1-12 of 12
Mariano Ponz-Sarvise
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Andrew L. Coveler, Matthew J. Reilley, Mark Zalupski, Teresa Macarulla, Christos Fountzilas, Mariano Ponz-Sarvisé, Adnan Nagrial, Nataliya V. Uboha, Sophia Frentzas, Michael Overman, Anne Noonan, Wells A. Messersmith, Nick Pavlakis, Niharika B. Mettu, Ina Bisha, Ying Wang, Paul Smith, Elina Murtomaki, Agata A. Bielska, Veronique Bragulat, Zachary A. Cooper, Rakesh Kumar, David R. Spigel
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF9.
https://doi.org/10.1158/1078-0432.CCR-24-0499
Published: 04 September 2024
View article titled, A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Open the PDF for A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R. Lindsay, Iwona Lugowska, James C. Yang, Federico Longo, Maria de Miguel, Mariano Ponz-Sarvise, Myung-Ju Ahn, Mahmut Gumus, Stephane Champiat, Antoine Italiano, Sébastien Salas, Ruth Perets, Cagatay Arslan, Byoung C. Cho, Stefan Evers, Christophe Boetsch, Daniel Marbach, David Dejardin, Nassim Sleiman, Caroline Ardeshir, Muriel Richard, Jehad Charo, Anton Kraxner, Nino Keshelava, Volker Teichgräber, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2945–2953.
https://doi.org/10.1158/1078-0432.CCR-23-2677
Published: 15 July 2024
View article titled, Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Open the PDF for Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer in another window
Includes: Supplementary data
Journal Articles

LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

Oihane Erice, Shruthi Narayanan, Iker Feliu, Rodrigo Entrialgo-Cadierno, Antonia Malinova, Caterina Vicentini, Elizabeth Guruceaga, Pietro Delfino, Marija Trajkovic-Arsic, Haritz Moreno, Karmele Valencia, Ester Blanco, Irati Macaya, Daniel Öhlund, Purvesh Khatri, Fernando Lecanda, Aldo Scarpa, Jens T. Siveke, Vincenzo Corbo, Mariano Ponz-Sarvise, Silve Vicent
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1137–1154.
https://doi.org/10.1158/1078-0432.CCR-22-0794
Published: 14 March 2023
View article titled, LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Open the PDF for LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth in another window
Includes: Supplementary data
Journal Articles

Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)

Bernadett Szabados, Mariano Ponz-Sarvisé, Robson Machado, Diego Saldana, Edward E. Kadel, Romain Banchereau, Fanny Bouquet, Marius Garmhausen, Thomas Powles, Carsten Schröder, On Behalf of the imCORE Working Group of Early Career Investigators (imFLAME)
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4083–4091.
https://doi.org/10.1158/1078-0432.CCR-22-0200
Published: 15 September 2022
View article titled, Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
Open the PDF for Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI) in another window
Includes: Supplementary data
Journal Articles

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliu, Mariano Ponz-Sarvise, David Gutierrez Abad, Paul Oberstein, Angela Alistar, Andres Muñoz, Ravit Geva, Carmen Guillén-Ponce, Mercedes Salgado Fernandez, Amnon Peled, Marya Chaney, Irit Gliko-Kabir, Liron Shemesh-Darvish, Debby Ickowicz, Ella Sorani, Shaul Kadosh, Abi Vainstein-Haras, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5020–5027.
https://doi.org/10.1158/1078-0432.CCR-21-0929
Published: 15 September 2021
View article titled, Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Open the PDF for Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial in another window
Includes: Supplementary data
Journal Articles

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

Mariano Ponz-Sarvise, Vincenzo Corbo, Hervé Tiriac, Dannielle D. Engle, Kristopher K. Frese, Tobiloba E. Oni, Chang-Il Hwang, Daniel Öhlund, Iok In Christine Chio, Lindsey A. Baker, Dea Filippini, Kevin Wright, Tashinga E. Bapiro, Pearl Huang, Paul Smith, Kenneth H. Yu, Duncan I. Jodrell, Youngkyu Park, David A. Tuveson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6742–6755.
https://doi.org/10.1158/1078-0432.CCR-19-1398
Published: 15 November 2019
View article titled, Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Open the PDF for Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack

Diego Salas-Benito, Ignacio Melero, Mariano Ponz-Sarvise
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5435–5437.
https://doi.org/10.1158/1078-0432.CCR-19-1753
Published: 13 September 2019
View article titled, Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack
Open the PDF for Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack in another window
Journal Articles

Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center

Javier Rodriguez, Silvestre Vicent, Ana Chopitea, Mariano Ponz-Sarvisé
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (16): 3787–3789.
https://doi.org/10.1158/1078-0432.CCR-18-0818
Published: 14 August 2018
View article titled, Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center
Open the PDF for Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center in another window
Journal Articles

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

Pedro Berraondo, Iñaki Etxeberria, Mariano Ponz-Sarvise, Ignacio Melero
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2716–2718.
https://doi.org/10.1158/1078-0432.CCR-18-0381
Published: 14 June 2018
View article titled, Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Open the PDF for Revisiting Interleukin-12 as a Cancer Immunotherapy Agent in another window
Journal Articles

Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing

Alvaro Teijeira, Iñaki Etxeberria, Mariano Ponz-Sarvise, Ignacio Melero
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4277–4279.
https://doi.org/10.1158/1078-0432.CCR-16-1072
Published: 31 August 2016
View article titled, Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing
Open the PDF for Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing in another window
Journal Articles

Abstract B16: Using human patient-derived organoids to identify genetic dependencies in pancreatic cancer

Lindsey A. Baker, Hervé Tiriac, Vincenzo Corbo, Sylvia F. Boj, Chang-il Hwang, Iok In Christine Chio, Danielle D. Engle, Myrthe Jager, Mariano Ponz-Sarvise, Mona S. Spector, Ana Gracanin, Tobiloba Oni, Kenneth H. Yu, Ruben van Boxtel, Meritxell Huch, Keith D. Rivera, John P. Wilson, Michael E. Feigin, Daniel Öhlund, Abram Handly-Santana, Christine M. Ardito-Abraham, Michael Ludwig, Ela Elyada, Brinda Alagesan, Giulia Biffi, Georgi N. Yordanov, Bethany Delcuze, Brianna Creighton, Kevin Wright, Youngkyu Park, Folkert H.M. Morsink, I. Quintus Molenaar, Inne H. Borel Rinkes, Edwin Cuppen, Yuan Hao, Ying Jin, Isaac J. Nijman, Christine Iacobuzio-Donahue, Steven D. Leach, Darryl J. Pappin, Molly Hammell, David S. Klimstra, Olca Basturk, Ralph H. Hruban, George Johan Offerhaus, Robert G.J. Vries, Hans Clevers, David A. Tuveson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B16.
https://doi.org/10.1158/1557-3265.PDX16-B16
Published: 15 August 2016
View article titled, Abstract B16: Using human patient-derived organoids to identify genetic dependencies in pancreatic cancer
Journal Articles

Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance

Mariano Ponz-Sarvisé, Paul A. Nguewa, María J. Pajares, Jackeline Agorreta, María D. Lozano, Miriam Redrado, Ruben Pio, Carmen Behrens, Ignacio I. Wistuba, Carlos E. García-Franco, Jesús García-Foncillas, Luis M. Montuenga, Alfonso Calvo, Ignacio Gil-Bazo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4155–4166.
https://doi.org/10.1158/1078-0432.CCR-10-3381
Published: 15 June 2011
View article titled, Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance
Open the PDF for Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance in another window
Includes: Supplementary data